Glycopeptides of the clinically important antibiotic drugs are glycosylated cyclic or polycyclic nonribosomal peptides. Glycopeptides such as vancomycin and teicoplanin are often used for the treatment of gram-positive bacteria in patients. The increased incidence of drug resistance and inadequacy of these therapeutics against gram-positive bacterial infections would be the formation and clinical development of more variable second generation of glycopeptide antibiotics: semisynthetic lipoglycopeptide analogs such as telavancin, dalbavancin, and oritavancin with improved activity and better pharmacokinetic properties. In this review, we describe the development of and bacterial resistance to vancomycin, teicoplanin, and semisynthetic glycopeptides (teicoplanin, dalbavancin, and oritavancin). The clinical influence of resistance to glycopeptides, particularly vancomycin, are also discussed.
INTRODUCTION

Glycopeptides
. These mechanisms of antimicrobial resistance were easily co-opted from glycopeptide producer actinomycetes, which use them to prevent selfharm when producing antibiotics (these mechanisms were less likely to be orchestrated by the pathogenic bacteria after prolonged treatment). Some van-like gene clusters with a high level of homology and an organization similar to those described in enterococci, were identified in many glycopeptide-producing actinomycetes, such as Amycolatopsis spp., which produces vancomycin, Actinoplanes teichomyceticus ATCC 31121, which produces teicoplanin, and Streptomyces toyocaensis, which produces the A47934 glycopeptide, but an understanding of their active function in affecting resistance is only at the beginning (4, 5) .
In this review, we describe the current understanding of the mechanisms of action and bacterial resistance to the natural and semisynthetic glycopeptides.
CHEMICAL STRUCTURE OF NATURAL GLYCOPEPTIDES
Glycopeptide antibiotics are often used to treat lifethreatening infections by multi-drug-resistant gram-positive organisms, such as S. aureus, Enterococcus spp., and Clostridium difficile. They are drugs of final resort against MRSA, which is these days a leading cause of communityacquired infections and results in high morbidity and death rates among patients with hospital-acquired infections (4, 6) . Natural glycopeptides composed of a cyclic peptide core comprised of seven amino acids, to which two aminosugars are bound to the amino acid core. Binding of this type of antibiotic to its target (D-Ala-D-Ala terminal end of peptidoglycan precursors) complexes via a set of five hydrogen bonds with the peptidic backbone of the therapeutic agent.
The presence of the chlorine or sugar moiety in oritavancin facilitates homo-dimerization, allowing for stronger interactions to the target site (7, 8) . A lipophilic side chain (present in teicoplanin and in all the semisynthetic glycopeptides) have been proposed to bind to bacterial membrane.
It increases antibacterial potency and prolongs half-life (Fig. 1) .
Vancomycin, produced by the actinomycete Amycolatopsis orientalis, was first introduced into clinical practice in 1958 (6) . Vancomycin contains proteinogenic (Tyr, Leu, Asn, Ala, and Glu) and nonproteinogenic amino acid residues and Enterococcus (4, 14) . Consequently, most of the semisynthetic glycopeptides were created by introducing hydrophobic moieties into the heptapeptide scaffold to ensure the membrane-anchoring ability, thus leading to more effective drugs (4, 9, 15) .
SEMISYNTHETIC GLYCOPEPTIDES
Semisynthetic glycopeptides telavancin, oritavancin, and 
MECHANISMS OF BACTERIAL RESISTANCE
Resistance to glycopeptides among enterococci is medi- But it has poor activity against vancomycin-resistant (vanA) enterococci and VRSA (4, 15, 31) . This lack of activity against VRE strains that contain the vanA gene differentiates dalbavancin from the other investigational glycopeptides, oritavancin and telavancin. 
